Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin versus dapagliflozin in acute decompensated heart failure
IRCT20240924063144N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in heart failure (HF) comparing Empagliflozin plus standard therapy with Dapagliflozin plus standard therapy (2 arms). Primary endpoint: Reduction in body weight. Started May 2026; status: completed.
02
Drugs
empagliflozindapagliflozin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on IRCT20240924063144N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240924063144N1.